Update on Immune Checkpoint Inhibitor Enterocolitis.

ABSTRACT:

Purpose of review

Immune checkpoint inhibitor (ICI) therapy revolutionized the treatment of multiple solid and hematologic malignancies. Yet, with it came profound inflammatory toxicities that mimic autoimmune diseases, termed immune-related adverse events (irAEs). Prominent among these is gastrointestinal inflammation, including a spectrum of gastritis, enteritis, and colitis. Here we synthesize an approach to immune checkpoint related enterocolitis (irEC) - including diagnostics and therapeutics - underpinned by new insights into the mechanism behind these phenomena.

Recent findings

This review presents updated insights on how to approach irEC, including novel approaches to selective immunosuppressive therapy, the role of fecal microbiota transplant, and the underlying cel

SUBMITTER: Kelly-Goss MR 

PROVIDER: S-EPMC9583048 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature